Overview

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Phase:
Phase 2
Details
Lead Sponsor:
Edison Pharmaceuticals Inc
PTC Therapeutics
Treatments:
Ubiquinone